Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus THIORIDAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus THIORIDAZINE HYDROCHLORIDE.
TARACTAN vs THIORIDAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also has significant anticholinergic and alpha-adrenergic blocking activity. It exhibits a high affinity for D2, 5-HT2A, and alpha1-adrenergic receptors.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
Adults: Initial 50-100 mg orally three times daily, gradually increasing to maximum 800 mg/day in divided doses. Usual maintenance: 200-800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
24-36 hours for the parent drug; extended in hepatic impairment and elderly; steady-state reached in 4-7 days.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites are excreted renally (approximately 30% of dose as metabolites) and fecally (approximately 20-30% via bile).
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic